A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Conditions

• Hepatic Insufficiency

Eligibility Criteria

Sex

ALL

Age

18 Years - 85 Years

Healthy Volunteers

Accepted

Interventions

• LY3841136 — DRUG
  Administered SC

Study Details

The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver. The researchers want to see how the medicine is absorbed and used by the body, and if it causes any side effects, in participants with mild, moderate, or severe liver damage, as well as in participants with normal liver function. For each participant, the study will last about 14 weeks, which will include a stay at the clinical research unit for 5 nights.

Key Dates

Start date

Feb 10, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2027

Completion

Mar 31, 2027

Study Design

Enrollment

36 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Eloralintide (Normal Hepatic Function)
  Eloralintide administered subcutaneously (SC)
• Experimental: Eloralintide (Mild Hepatic Impairment)
  Eloralintide administered SC
• Experimental: Eloralintide (Moderate Hepatic Impairment)
  Eloralintide administered SC
• Experimental: Eloralintide (Severe Hepatic Impairment)
  Eloralintide administered SC

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136 [ Time Frame: Predose on Day 1 up to Day 71 ]

Central Contacts

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  1-317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (2)

Find similar trials in Orlando, FL

Related Studies

• A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
  PHASE1 · Recruiting · X4 Pharmaceuticals · Montclair, California